Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-FR Version v4-FR
Language French French
Date Updated 2020-07-03 2020-04-07
Drug Identification Number 02182777 02182777
Brand name METHOTREXATE INJECTION USP METHOTREXATE INJECTION USP
Common or Proper name Methotrexate Injection USP Methotrexate Injection USP
Company Name PFIZER CANADA ULC PFIZER CANADA ULC
Ingredients METHOTREXATE METHOTREXATE
Strength(s) 25MG 25MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRA-ARTERIAL INTRAMUSCULAR INTRAVENOUS INTRA-ARTERIAL INTRAMUSCULAR INTRAVENOUS
Packaging size 5 x 2mL multidose vial 5 x 2mL multidose vial
ATC code L01BA L01BA
ATC description ANTIMETABOLITES ANTIMETABOLITES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-04-07 2020-04-07
Estimated end date 2020-07-06
Actual end date 2020-07-03
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments Ordering restrictions will apply. Ample stock of the 2mL single pack remains available.
Health Canada comments